Anne  McGeorge net worth and biography

Anne McGeorge Biography and Net Worth

Anne McGeorge has almost 40 years of experience providing strategic guidance and operational oversight to health care organizations. Ms. McGeorge currently serves as the Chairman of the Board of Directors, as well as a member of the Compensation Committee, at The Oncology Institute, Inc. She also serves on the Board of Directors, as well as the Audit Committee Chair of two private companies, CitiusTech, a health care technology company, and Nimbus Therapeutics, LLC, a biotech company. She is also on the board of CLEAR Insurance, a Cayman based captive insurance company, the National Marrow Donor Program (aka Be The Match), a 501(c)(3) organization, the William and Mary Raymond Mason School of Business Foundation, and is on the advisory board at FCA Healthcare Innovations, a venture capital company. Additionally, Ms. McGeorge previously served on the Board of Directors of SOC Telemed, Inc. from October 2020 until it was acquired by Patient Square Capital, Inc. Ms. McGeorge is also on the adjunct faculty at the University of North Carolina at Chapel Hill. Prior to her retirement in July 2017, Ms. McGeorge worked at Grant Thornton LLP where she routinely advised clients on audit, tax, and financial matters relating to the healthcare industry. During her time at Grant Thornton LLP, Ms. McGeorge was Managing Partner of Grant Thornton LLP’s Health Care Industry Practice from January 2006 to July 2017, as well as Global Managing Partner for Grant Thornton International’s Health Care Industry Practice from August 2015 to July 2017. Ms. McGeorge was formerly a partner at Deloitte LLP from 2002 to 2005 and at Arthur Andersen LLP from 1997 to 2002. Ms. McGeorge received a B.B.A., Business, Accounting from the College of William and Mary, and an M.S., Accounting/Taxation from the University of Virginia. LinkedIn Profile

What is Anne McGeorge's net worth?

The estimated net worth of Anne McGeorge is at least $135.61 thousand as of August 10th, 2026. Ms. McGeorge owns 1,250 shares of Dianthus Therapeutics stock worth more than $135,613 as of August 12th. This net worth approximation does not reflect any other assets that Ms. McGeorge may own. Learn More about Anne McGeorge's net worth.

How do I contact Anne McGeorge?

The corporate mailing address for Ms. McGeorge and other Dianthus Therapeutics executives is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . Dianthus Therapeutics can also be reached via phone at 857-242-0170 and via email at [email protected]. Learn More on Anne McGeorge's contact information.

Has Anne McGeorge been buying or selling shares of Dianthus Therapeutics?

During the last ninety days, Anne McGeorge has sold $844,827.50 of Dianthus Therapeutics stock. Most recently, Anne Mcgeorge sold 7,750 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a transaction totalling $844,827.50. Following the completion of the sale, the director now directly owns 1,250 shares of the company's stock, valued at $136,262.50. Learn More on Anne McGeorge's trading history.

Who are Dianthus Therapeutics' active insiders?

Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Anne McGeorge (Director), Simrat Randhawa (Insider), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.

Are insiders buying or selling shares of Dianthus Therapeutics?

During the last twelve months, insiders at the sold shares 17 times. They sold a total of 843,865 shares worth more than $64,836,552.05. The most recent insider tranaction occured on August, 10th when Director Anne Mcgeorge sold 7,750 shares worth more than $844,827.50. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.

Information on this page was last updated on 8/10/2026.

Anne McGeorge Insider Trading History at Dianthus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2026Sell7,750$109.01$844,827.501,250View SEC Filing Icon  
See Full Table

Anne McGeorge Buying and Selling Activity at Dianthus Therapeutics

This chart shows Anne Mcgeorge's buying and selling at Dianthus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dianthus Therapeutics Company Overview

Dianthus Therapeutics logo
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Read More

Today's Range

Now: $109.49
Low: $108.36
High: $110.22

50 Day Range

MA: $95.71
Low: $76.42
High: $112.64

2 Week Range

Now: $109.49
Low: $19.75
High: $114.55

Volume

46,939 shs

Average Volume

966,317 shs

Market Capitalization

$5.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22